Flyer

Translational Biomedicine

  • ISSN: 2172-0479
  • Journal h-index: 12
  • Journal CiteScore: 8.06
  • Journal Impact Factor: 1.0
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • ResearchBible
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Google Scholar
  • Secret Search Engine Labs
  • ResearchGate
Share This Page

Abstract

Unravelling the Role of Stem Cells in Chronic Myeloid Leukaemia and Potential Treatments

Jeevan Francis

Chronic Myeloid Leukaemia (CML) is a disorder of the haematopoietic system characterised by the malignant clonal growth of bone marrow cells, specifically haematopoietic stem cells (HSCs), which are capable of giving rise to all lineages of blood cells. In essence, CML is a condition where transformed HSCs give rise to cells of myeloid lineage, e.g. platelets, neutrophils etc, causing them to accumulate in the circulating blood. The aim of this paper was to understand and review the role of stem cells (SCs) and Cancer Stem Cells (CSCs) in CML, current strategies for targeting CSCs, potential targets for CML CSC treatment such as histone deacetylase inhibition, autophagy inhibitors, p53 activation by SIRT1 inhibitors, HIF inhibition, and the regulation of c-myc.